Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Future Oncol
; 17(32): 4237-4247, 2021 Nov.
Article
en En
| MEDLINE
| ID: mdl-34423676
Lay abstract Tyrosine kinase inhibitor medications like crizotinib may work as a first treatment for people with non-small-cell lung cancer (NSCLC) that has spread to other parts of the body and has the ALK+ mutation (ALK+ NSCLC) in tumor testing. However, many people stop responding to treatment with crizotinib. Brigatinib and alectinib are tyrosine kinase inhibitor medications that may be effective in people with ALK+ NSCLC who have stopped responding to crizotinib treatment. We describe the need for and design of a study comparing brigatinib with alectinib in people with ALK+ NSCLC whose disease worsened on crizotinib.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Compuestos Organofosforados
/
Piperidinas
/
Pirimidinas
/
Carbazoles
/
Carcinoma de Pulmón de Células no Pequeñas
/
Crizotinib
/
Quinasa de Linfoma Anaplásico
/
Neoplasias Pulmonares
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Reino Unido
Pais de publicación:
Reino Unido